Get the Stockscreener App
3.73
10.12%
-0.42
After Hours:
3.75
0.02
+0.54%
Cabaletta Bio Inc stock is traded at $3.73, with a volume of 6.71M.
It is down -10.12% in the last 24 hours and up +23.92% over the past month.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
See More
Previous Close:
$4.15
Open:
$4.22
24h Volume:
6.71M
Relative Volume:
2.33
Market Cap:
$415.24M
Revenue:
-
Net Income/Loss:
$-167.86M
P/E Ratio:
-1.6263
EPS:
-2.2935
Net Cash Flow:
$-132.31M
1W Performance:
+34.17%
1M Performance:
+23.92%
6M Performance:
+50.40%
1Y Performance:
+224.35%
1-Day Range:
$3.53
$4.23
1-Week Range:
$2.715
$4.23
52-Week Range:
$1.11
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.73 | 462.00M | 0 | -167.86M | -132.31M | -2.2935 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Number of shareholders of Cabaletta Bio, Inc. – BMV:CABA - TradingView
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
CABA Stock Pops As $30 Target, Funding And Manufacturing Align - timothysykes.com
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta Bio prices $150 million public offering - The Pharma Letter
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting - MyChesCo
Cabaletta Bio | 8-K: Current report - Moomoo
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy - TechStock²
CABA Reiterates by Cantor Fitzgerald -- Price Target Maintained at $30 - GuruFocus
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
Cabaletta Bio (CABA) Reports Progress in Pemphigus Vulgaris Trea - GuruFocus
Cabaletta Bio Shares Rise After $150M Underwritten Offering Prices - Moomoo
Guggenheim reiterates Cabaletta Bio stock rating on trial data By Investing.com - Investing.com South Africa
Guggenheim reiterates Cabaletta Bio stock rating on trial data - Investing.com
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big - Benzinga
Cabaletta Bio prices $150 million stock offering at $2.90 - Investing.com UK
Cabaletta Bio prices $150 million stock offering at $2.90 By Investing.com - Investing.com South Africa
Cabaletta Bio Prices $150 Million Stock Offering - Moomoo
Cabaletta Bio stock jumps on $150M offering pricing - Investing.com
Cabaletta Bio stock jumps on $150M offering pricing By Investing.com - Investing.com South Africa
Cabaletta Bio prices $150M stock offering - MSN
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering - The Manila Times
Cabaletta Bio Announces $150 Million Equity Offering - TipRanks
Cabaletta Bio (NASDAQ: CABA) raises $150M via 51.7M-share offering - Stock Titan
Cabaletta Bio (NASDAQ: CABA) prices $150M equity raise to fund rese-cel - Stock Titan
Backed by Eli Lilly, Cabaletta sells $150M in new shares - Stock Titan
Cabaletta Bio (NASDAQ: CABA) to share new rese-cel RESET-PV data at ASGCT 2026 - Stock Titan
Cabaletta Bio, Inc. $CABA Shares Bought by Jennison Associates LLC - MarketBeat
CABA News | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Stock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA) - MarketBeat
H.C. Wainwright reiterates Cabaletta Bio stock rating on manufacturing scalability - Investing.com Australia
Cabaletta Bio enters agreement with California company to manufacture one of its cell therapies - Pennsylvania Business Report -
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com South Africa
CABA Forms Agreement with Cellares for Cost-Effective Cell Thera - GuruFocus
CABA Gains Strategic Partnership for Efficient Rese-Cel Producti - GuruFocus
Cabaletta Bio | DEF 14A: Definitive information statements - Moomoo
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):